| Literature DB >> 27035436 |
Antonio Montresor1, Arminder Deol2, Natacha À Porta1, Nam Lethanh3, Dina Jankovic4.
Abstract
BACKGROUND: Estimating the reduction in levels of infection during implementation of soil-transmitted helminth (STH) control programmes is important to measure their performance and to plan interventions. Markov modelling techniques have been used with some success to predict changes in STH prevalence following treatment in Viet Nam. The model is stationary and to date, the prediction has been obtained by calculating the transition probabilities between the different classes of intensity following the first year of drug distribution and assuming that these remain constant in subsequent years. However, to run this model longitudinal parasitological data (including intensity of infection) are required for two consecutive years from at least 200 individuals. Since this amount of data is not often available from STH control programmes, the possible application of the model in control programme is limited. The present study aimed to address this issue by adapting the existing Markov model to allow its application when a more limited amount of data is available and to test the predictive capacities of these simplified models.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27035436 PMCID: PMC4817985 DOI: 10.1371/journal.pntd.0004371
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
WHO classification of intensity of soil-transmitted helminth (STH) infections corresponding to condition states in the Markov nomenclature [1].
| Condition State 1 | Condition State 2 | Condition State 3 | Condition State 4 | |
|---|---|---|---|---|
| STH species | Zero eggs (epg) | Infections of light intensity (epg) | Infections of moderate intensity (epg) | Infections of heavy intensity (epg) |
| 0 | 1–4999 | 5000–49 999 | > 50 000 | |
| 0 | 1–999 | 1000–9999 | > 10 000 | |
| Hookworms | 0 | 1–1999 | 2000–3999 | > 4000 |
epg = eggs per gram of faeces.
Fig 1Condition states (represented by the four circles) and transition probabilities (represented by the 16 arrows) for cases of hookworm infection treated with albendazole once per year (data from Uganda).
The CS and TP were calculated by analysing individual baseline and follow up data from 1423 individuals. The baseline prevalence of hookworm infection was 55% (52% of light-intensity infection, 2% of moderate-intensity infection and 1% of heavy-intensity infection). After one year of implementation of control measures, 69% of the light-intensity infections (CS2) were reduced to “zero eggs”, 29% of the CS2 remained as light-intensity infections and 2% increased to moderate-intensity infections.
Minimum requirements to run original model (OM), simplified model 1 (SM1) and simplified model 2 (SM2).
| Model | Minimum requirements | |
|---|---|---|
| Baseline data | 1 year follow-up data | |
| OM | Survey of 200 individuals, | Survey of the same 200 individuals, |
| SM1 | Survey of 125 individuals | No follow-up data required |
| SM2 | Survey of 125 individuals, prevalence of | No follow-up data required |
Standard transition probability matrix sets (TPMS) and the datasets used to develop TPMS.
| TPMS | First round of drug distribution | Second round of drug distribution | Dataset used to develop standard TPMS | no. of school-aged children | Comments (assumption) | Ref. |
|---|---|---|---|---|---|---|
| TPMS 1 | Albendazole | Albendazole | Viet Nam | 366 | Calculated form study implementing the intervention | [ |
| TPMS 2 | Mebendazole | Mebendazole | Tanzania (Zanzibar) | 1311 | Calculated form study implementing the intervention | [ |
| TPMS 3 | Albendazole | No second round intervention | Uganda | 1423 | Calculated form study implementing the intervention | [ |
| TPMS 4 | Mebendazole | No second round intervention | Tanzania (Zanzibar) | 1324 | Calculated form study implementing the intervention | [ |
| TPMS 5 | Albendazole + Ivermectin | Albendazole | Viet Nam | 366 | Similar to TPMS1 (slightly more | [ |
| Tanzania (Zanzibar) | 301 | active in hookworms) | ||||
| TPMS 6 | Albendazole + Ivermectin | Mebendazole | Viet Nam and | 366 | Equal to TPMS5 | [ |
| Tanzania (Zanzibar) | 1311 | |||||
| TPMS 7 | Albendazole + Diethylcarbamazine | Albendazole | Viet Nam | 366 | Equal to TPMS1 (absence of impact of DEC on STH) | [ |
| TPMS 8 | Albendazole + Diethylcarbamazine | Mebendazole | Tanzania (Zanzibar) | 1311 | Equal to TPMS2 (absence of impact of DEC on STH) | [ |
| TPMS 9 | Albendazole + Ivermectin | No second round intervention | Tanzania (Zanzibar) | 301 | Calculated form study implementing the intervention | [ |
| TPMS 10 | Albendazole+ Diethylcarbamazine | No second round intervention | Uganda | 1423 | Equal to TPMS3 (absence of impact of DEC on STH) | [ |
* Interventions administered to the entire population in a district in the context of the global programme for elimination of lymphatic filariasis; their impact on STH prevalence in the community is larger than the administration of benzimidazoles to children only.
Datasets used to test the model.
| Country | Sample size | No. of surveys | Baseline prevalence | Drug used | Number of years of intervention (years) | Frequency of intervention | Model tested | Ref. | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-up | Hookworms | |||||||||
| Viet Nam | 210–261 | 1 | 5 | 30% | 29% | 76% | ALB | 1–6 | 2/year | OM-SM1-SM2 | [ |
| Uganda | 1423 | 1 | 3 | 2% | 2% | 59% | ALB | 1–3 | 1/year | OM-SM1-SM2 | [ |
| Zambia | 490 | 1 | 2 | 22% | 0 | 7.8% | ALB+IVR | 1.5 | 1/year | SM1-SM2 | [ |
| Lao PDR | 2885 | 1 | 1 | 61% | 43% | 19% | ALB | 2 | 2/year | SM1-SM2 | [ |
| Myanmar, Pin Lung | 250 | 1 | 1 | 23% | 3% | 5% | ALB | 5 | 2/year | SM1-SM2 | [ |
| Myanmar Phhyu | 250 | 1 | 1 | 50% | 55% | 10% | ALB | 5 | 2/year | SM1-SM2 | [ |
| Myanmar, Nyangdone | 250 | 1 | 1 | 63% | 88% | 0% | ALB | 5 | 2/year | SM1-SM2 | [ |
| Myanmar, Meik | 250 | 1 | 1 | 58% | 84% | 12% | ALB | 5 | 2/year | SM1-SM2 | [ |
| UR Tanzania | 1192 | 1 | 1 | 98% | 90% | 97% | ALB+IVR | 13 | 1/year | SM1-SM2 | [ |
| Nepal | 711 | 1 | 1 | 22% | 19% | 64% | ALB | 2 | 1/year | SM1-SM2 | [ |
| India, A. Pradesh | 217 | 1 | 1 | 73% | 67% | 0 | ALB | 0.75 | 1/year | SM1-SM2 | [ |
| India, W. Bengala | 126 | 1 | 2 | 54% | 0 | 0 | ALB | 0.5–1 | 2/year | SM2 | [ |
| India, Tamil Nadu | 325 | 1 | 2 | 55% | 17% | 5% | ALB+DEC | 1–2 | 1/year | SM2 | [ |
| Cambodia, Achen | 50 | 1 | 1 | 25% | 2% | 55% | MEB | 5 | 1/year | SM2 | [ |
| Cambodia, Chartnol | 50 | 1 | 1 | 10% | 2% | 46% | MEB | 5 | 1/year | SM2 | [ |
| Cambodia, Sambock | 50 | 1 | 1 | 16% | 2% | 45% | MEB | 5 | 1/year | SM2 | [ |
| Cambodia, Srekhoeun | 50 | 1 | 1 | 14% | 2% | 50% | MEB | 5 | 1/year | SM2 | [ |
| Cambodia, Sdau | 50 | 1 | 1 | 51% | 2% | 86% | MEB | 5 | 1/year | SM2 | [ |
| Cambodia, Koh Sneg | 50 | 1 | 1 | 34% | 2% | 55% | MEB | 5 | 1/year | SM2 | [ |
| Cambodia, K. Chan Tuk | 50 | 1 | 1 | 70% | 2% | 67% | MEB | 5 | 1/year | SM2 | [ |
| Seychelles, children | 1058 | 1 | 2 | 18% | 53% | 6% | MEB | 5 | 2/year | SM2 | [ |
| Seychelles,women | 338 | 1 | 1 | 10% | 36% | 9% | MEB | 2 | 2/year | SM2 | [ |
| Bangladesh | 223 | 1 | 1 | 45% | 56% | 73% | ALB | 0.5 | 1/year | SM2 | [ |
| Oman | 860 | 1 | 5 | 40% | 0 | 0.5% | ALB | 1–5 | 1/year | SM2 | [ |
| Ghana | 1011 | 1 | 2 | 87% | NA | NA | ALB | 1–2 | 2/year | SM2 | [ |
| Sri Lanka | 177 | 1 | 5 | 84% | 85% | 72% | MEB | 1–6 | 2/year | SM2 | [ |
| 26 | 45 | ||||||||||
ALB, albendazole; MEB = mebendazole; IVR, ivermectin; DEC, diethylcarbamazine OM, original model; SM1, Simplified Model 1; SM2, Simplified Model 2
Mean discrepancy and accuracy of the predictions obtained by the Markov original (OM) and simplified models (SM1 and SM2).
| Accuracy of the predictions | ||||
|---|---|---|---|---|
| Mean discrepancies between predicted and observed prevalence in absolute percentage points | Proportion of predictions ≤ 5 percentage points from the observed values | Proportion of predictions > 5 and ≤ 10 percentage points from the observed values | Proportion of predictions > 10 percentage points from the observed values | |
| OM | ||||
| 2.66 (range 0–7) | 83.3% | 16.7% | 0% | |
| 0.66 (range 0–3) | 100% | 0% | 0% | |
| hookworm | 6.16 (range 0–14) | 50% | 33.3% | 16.7% |
| SM1 | ||||
| 5 (range 0–27) | 66.7% | 27.8% | 5.6% | |
| 3.22 (range 0–15) | 83.3% | 5.6% | 11.1% | |
| hookworm | 6.41 (range 0–25) | 58.8% | 11.8% | 29.4% |
| SM2 | ||||
| 10.6 (range 0–60) | 60.5% | 9.8% | 30.2% | |
| 6.4 (range 0–41) | 74.4% | 2.3% | 23.3% | |
| hookworm | 8.4 (range0–44) | 46.7% | 24.4% | 28.9% |
Fig 2Relationship between observed and prevalence predicted by the original model (graph a) and simplified models (graphs a and b).
Linear trend is included.